Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

EORTC and the management of clinical trial data

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Molecular targeting in cancer and the impact on personalised medicine

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Phase III trial results raise questions about the future of lung cancer vaccination

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Adding cediranib to chemo improves PFS for metastatic cervical cancer

Rare cancers and the difficulties in making clinical decisions